OPAT monitoring: a structure that protects patients and supports billing

Monitoring is where OPAT programs either demonstrate their value or quietly accumulate risk. The same structure that keeps patients safe is also the record that supports the practice's cognitive billing — which is a good reason to design it once, properly.

The schedule

Standardise by therapy class rather than deciding patient by patient. Agent-specific toxicity monitoring, renal and hepatic function, therapeutic drug monitoring where indicated, and inflammatory markers where they inform response. Write it down, publish it internally, and treat deviations as decisions to be documented rather than as ordinary variation.

Getting the results back

Published surveys of OPAT programs identify timely access to laboratory results as one of the most commonly reported challenges. This is a logistics problem with clinical consequences: a monitoring schedule that produces results nobody sees on time provides documentation without safety.

• Name the responsible reviewer and the backup, with defined turnaround expectations.
• Agree in advance which laboratory the patient uses, and confirm results route back to you — not only to the referring service.
• Define critical-value handling explicitly, including out of hours.

The weekly review

A documented weekly review per active patient covering: clinical response, laboratory trend, line status, adherence and tolerability, planned duration and any change in plan. Recorded as a clinical decision with reasoning — which is what makes it both defensible and billable where the encounter supports it.

The pathways to define in advance

1. Line complications — occlusion, infection, displacement. Who assesses, where, and how quickly.
2. Adverse drug reactions — thresholds for holding therapy, and who may make that call.
3. Clinical deterioration — the readmission pathway and who is notified.
4. Non-adherence or loss of contact — escalation, and the point at which therapy is formally discontinued.
5. Out-of-hours cover — the arrangement, in writing, communicated to the patient at the start of therapy.

What to measure

Therapy completion rate, unplanned readmission during therapy, line complication rate per 1,000 catheter days, and adverse events requiring therapy change. These are the numbers that make the institutional value case — and the ones any hospital partner will ask for when a coverage agreement is being negotiated.